Head-To-Head Comparison: OptimizeRx (NASDAQ:OPRX) and SOPHiA GENETICS (NASDAQ:SOPH)

OptimizeRx (NASDAQ:OPRX – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of current ratings and price targets for OptimizeRx and SOPHiA GENETICS, as reported by MarketBeat.com.

Get OptimizeRx alerts:

OptimizeRx currently has a consensus target price of $11.57, suggesting a potential upside of 37.92%. SOPHiA GENETICS has a consensus target price of $10.00, suggesting a potential upside of 24.53%. Given OptimizeRx’s stronger consensus rating and higher possible upside, analysts clearly believe OptimizeRx is more favorable than SOPHiA GENETICS.

Profitability

This table compares OptimizeRx and SOPHiA GENETICS’s net margins, return on equity and return on assets.

Risk and Volatility

OptimizeRx has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Insider & Institutional Ownership

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares OptimizeRx and SOPHiA GENETICS”s gross revenue, earnings per share (EPS) and valuation.

OptimizeRx has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Summary

OptimizeRx beats SOPHiA GENETICS on 13 of the 14 factors compared between the two stocks.

About OptimizeRx

(Get Free Report)

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.